心通医疗-B(02160)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02160 心通医疗-B

3.430

+0.650

+23.38%

最高--	最低--	成交量3,905万
今开--	昨收2.780	日振幅25.90%
总市值82.52亿	流通市值82.52亿	总股本24.06亿
成交额1.26亿	换手率1.62%	流通股本24.06亿
市净率2.27	ROE--	每股收益-0.09
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

Data provider: Ningxia XSRK Technology Limited

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"market":"HK","stockBase":{"symbol":"02160","market":"HK","secType":"STK","nameCN":"心通医疗-B","latestPrice":3.43,"timestamp":1656058087016,"preClose":2.78,"halted":0,"volume":39047192,"delay":0,"change":0.65,"changeRate":0.233813,"floatShares":2405832687,"shares":2405832687,"eps":-0.09232991,"lyrEps":-0.09233,"pbRate":2.27,"psRate":34.99,"amount":126016756,"amplitude":0.258993,"volumeRatio":5.070963135341974,"dividePrice":0,"prevYearClose":3.87,"fiveDayClose":2.81,"twentyDayClose":2.14},"adData":{"groupTypeList":[],"userSplitList":[]},"requestUrl":"/m/hq/s/02160","defaultTab":"news","newsList":[{"id":"2241361862","title":"港股异动蛭⒋匆搅(00853)涨近7% 与心通医疗(02160)订立2022年服务采购框架","url":"https://stock-news.laohu8.com/highlight/detail?id=2241361862","media":"金融界网站","top":-1,"share":"https://www.laohu8.com/m/news/2241361862?lang=zh_CN&edition=full","pubTime":"2022-06-08 11:51","pubTimestamp":1654660301,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，微创医疗(00853)早盘高开逾2%，盘中涨幅持续扩大，一度涨超8%。截至11时50分，涨6.94%，报价18.18港元，成交额1.52亿。　　据心通医疗公布，于2022年6月7日，上海微创心通(为其本身及代表其附属公司)与微创医疗(为其本身及代表除集团以外的附属公司)订立2022年服务采购框架协议，据此，上海微创心通将向分拆後微创医疗集团采购推广服务及患者健康管理服务。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"source_url":"http://hk.jrj.com.cn/2022/06/08115136711900.shtml","is_publish_highlight":false},{"id":"2241354478","title":"港股公告掘金 | 积极响应国家“稳就业、保民生”的工作要求 加大优质高等教育学位供给 这家公司民办本科院校专升本学额同比增加1.5倍","url":"https://stock-news.laohu8.com/highlight/detail?id=2241354478","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2241354478?lang=zh_CN&edition=full","pubTime":"2022-06-08 08:09","pubTimestamp":1654646988,"startTime":"0","endTime":"0","summary":"公告称，公司落实将中央政府“稳就业、保民生”的工作要求，加大优质高等教育学位供给;深入推进“质量优先”战略，提质培优，办学质量进一步获得社会认可;加快推进校区改建升级与扩建，校区扩容能提供更多学位。公司的普通本专科招生学额正在陆续获得批准，预期将大幅增长。截止今年3月29日，公司VitaFlow以及VitaFlow Liberty 已经覆盖超过300家医院，并在其中180家医院占据领先地位。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"source_url":"http://www.zhitongcaijing.com/content/detail/735209.html","is_publish_highlight":false},{"id":"2241074272","title":"心通医疗-B(02160.HK)：上海微创心通与微创医疗订立2022年服务采购框架协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2241074272","media":"金融界网站","top":-1,"share":"https://www.laohu8.com/m/news/2241074272?lang=zh_CN&edition=full","pubTime":"2022-06-07 21:23","pubTimestamp":1654608200,"startTime":"0","endTime":"0","summary":"格隆汇6月7日丨心通医疗-B(02160.HK)公布，于2022年6月7日，上海微创心通(为其本身及代表其附属公司)与微创医疗(为其本身及代表除集团以外的附属公司)订立2022年服务采购框架协议，据此，上海微创心通将向分拆後微创医疗集团采购(i)推广服务及(ii)患者健康管理服务。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"source_url":"http://hk.jrj.com.cn/2022/06/07212336710524.shtml","is_publish_highlight":false},{"id":"2241779025","title":"高瓴很“忙”：一边澄清传闻 一边收获IPO 投资小秘密也曝光？","url":"https://stock-news.laohu8.com/highlight/detail?id=2241779025","media":"科创板日报记者 陈美","top":-1,"share":"https://www.laohu8.com/m/news/2241779025?lang=zh_CN&edition=full","pubTime":"2022-06-05 08:22","pubTimestamp":1654388520,"startTime":"0","endTime":"0","summary":"拆分上市，已成为高瓴的一张王牌。除微创系以外，记者发现，与高瓴合作的公司中，大族激光、丽珠集团、协鑫科技、凯莱英、金斯瑞等多家公司均有拆分上市，或者二次上市的计划。","market":"hk","thumbnail":"https://img.cls.cn/images/20220605/tQ4z20B27T.jpg","type":0,"news_type":0,"thumbnails":["https://img.cls.cn/images/20220605/tQ4z20B27T.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"source_url":"https://www.chinastarmarket.cn/detail/1033737","is_publish_highlight":false},{"id":"2238065633","title":"心通医疗-B(02160)委任赵亮为执行董事","url":"https://stock-news.laohu8.com/highlight/detail?id=2238065633","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2238065633?lang=zh_CN&edition=full","pubTime":"2022-05-26 22:54","pubTimestamp":1653576873,"startTime":"0","endTime":"0","summary":"智通财经APP讯，心通医疗-B(02160)公布，赵亮已获委任为执行董事及公司的子公司上海微创心通医疗科技有限公司的董事，自2022年5月26日起生效。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"source_url":"http://www.zhitongcaijing.com/content/detail/729746.html","is_publish_highlight":false},{"id":"2237489873","title":"中泰证券：TAVR耗材纳入上海医保 头部创新产品或加速放量","url":"https://stock-news.laohu8.com/highlight/detail?id=2237489873","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2237489873?lang=zh_CN&edition=full","pubTime":"2022-05-23 10:38","pubTimestamp":1653273502,"startTime":"0","endTime":"0","summary":"中泰证券主要观点如下:TAVR耗材按80%比例纳入医保支付范围，相关产品有望加速放量。本次通知指出开展例数少于30例的医疗机构不纳入考核，是否纳入报销范围尚未明确，如果对应医疗机构的TAVR耗材未能纳入医保支付，相关医院或将有更大的动力加快开展TAVR手术以达到报销要求;如果对应机构也纳入报销体系，同样也有助于相关产品的终端放量。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"source_url":"http://www.zhitongcaijing.com/content/detail/727160.html","is_publish_highlight":false},{"id":"2232037647","title":"心通医疗-B(02160.HK)副总裁辞任","url":"https://stock-news.laohu8.com/highlight/detail?id=2232037647","media":"AAFN","top":-1,"share":"https://www.laohu8.com/m/news/2232037647?lang=zh_CN&edition=full","pubTime":"2022-05-03 08:59","pubTimestamp":1651539589,"startTime":"0","endTime":"0","summary":"心通医疗-B  公布，由於个人职业发展原因，吴国佳已辞任执行董事兼副总裁(销售及营销)，自上月30日起生效。(na/da)~阿思达克财经新闻网址: www.aastocks.com","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"source_url":"http://www.aastocks.com/apps/data/iphone/news/newscontent.aspx?newsid=NOW.1181351&style=5&chgstyle=1&categoryid=stock&width=320&market_id=hk&fontary=3&platform=iPhone&language=sc&isfirstreq=1&sourceid=aafn&datatype=0","is_publish_highlight":false},{"id":"2232277157","title":"心通医疗-B(02160)：应用AltaValve™及新一代经房间隔输送系统完成经导管二尖瓣置换手术","url":"https://stock-news.laohu8.com/highlight/detail?id=2232277157","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2232277157?lang=zh_CN&edition=full","pubTime":"2022-05-03 06:28","pubTimestamp":1651530538,"startTime":"0","endTime":"0","summary":"两例手术均应用新一代经房间隔输送系统将AltaValve输送到指定位置，且二尖瓣反流症状在术后均显着降低。AltaValve也是目前已知的全球唯一一款可在完全释放后输送系统撤出前实现全回收功能的TMVR器械。公司拥有AltaValve及新一代经房间隔输送系统在中国内地、中国香港、中国澳门及中国台湾的独家商业权利。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"source_url":"http://www.zhitongcaijing.com/content/detail/718054.html","is_publish_highlight":false},{"id":"2231230340","title":"心通医疗-B(02160)：吴国佳辞任执行董事兼副总裁(销售及营销)","url":"https://stock-news.laohu8.com/highlight/detail?id=2231230340","media":"智通财经网","top":-1,"share":"https://www.laohu8.com/m/news/2231230340?lang=zh_CN&edition=full","pubTime":"2022-04-29 23:16","pubTimestamp":1651245370,"startTime":"0","endTime":"0","summary":"心通医疗-B(02160)公布，由于个人职业发展原因，吴国佳已辞任公司执行董事兼副...","market":"sh","thumbnail":"https://img.zhitongcaijing.com/gonggao/ztcj_announce_23.jpeg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/gonggao/ztcj_announce_23.jpeg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"source_url":"http://www.zhitongcaijing.com/content/detail/717788.html","is_publish_highlight":false},{"id":"2228504459","title":"心通医疗-B(02160.HK)获Shanghai MicroPort增持2036.4万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2228504459","media":"格隆汇","top":-1,"share":"https://www.laohu8.com/m/news/2228504459?lang=zh_CN&edition=full","pubTime":"2022-04-19 07:37","pubTimestamp":1650325037,"startTime":"0","endTime":"0","summary":"格隆汇APP获悉，根据联交所最新权益披露资料显示，2022年4月13日，心通医疗-B(02160.HK)获Shanghai MicroPort Limited在场内以每股均价2.8635港元增持2036.4万股，涉资约5831.2万港元。增持后，Shanghai MicroPort Limited最新持股数目为1,100,978,680股，持股比例由45.37%上升至46.22%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202204190737237c8faff8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202204190737237c8faff8&s=b","is_publish_highlight":false},{"id":"2226671509","title":"【港股通】心通医疗-Ｂ(02160)盘前高开4.17% 获股东增持1196.4万股公司股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2226671509","media":"凤凰网港股","top":-1,"share":"https://www.laohu8.com/m/news/2226671509?lang=zh_CN&edition=full","pubTime":"2022-04-11 09:35","pubTimestamp":1649640941,"startTime":"0","endTime":"0","summary":"心通医疗-Ｂ(02160)盘前高开4.17%，报3.0港元，成交额21.30万港元。公司公布，自4月6日至8日，控股股东微创医疗科学子公司Shanghai MicroPort Limited按每股平均价约2.8723元，于公开市场购入合共1196.4万股公司股份，涉资3436.42万元。紧接购股事项后，Shanghai MicroPort Limited持有约10.9亿股股份，占全部已发行股本约45.37%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"source_url":"http://hknews.szfuit.com/newRssInfo/feed?original_id=98df95c1aca1544ee863974d5f882b06","is_publish_highlight":false},{"id":"2226509515","title":"港股异动︱心通医疗-B(02160)涨超4% 获股东微创医疗科学增持1196.4万股 涉资约达3436万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2226509515","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2226509515?lang=zh_CN&edition=full","pubTime":"2022-04-11 09:27","pubTimestamp":1649640454,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，心通医疗-B(02160)公布，该公司已获控股股东微创医疗科学有限公司告知，自2022年4月6日至4月8日，Shanghai MicroPort Limited(微创医疗科学有限公司的全资子公司，及该公司控股股东)按平均价每股约2.8723港元，于公开市场购入合共1196.4万股该公司股份(购股事项)。截至9时20分，涨4.17%，报价3.00港元，成交额21.3万。紧接购股事项后，Shanghai MicroPort Limited持有约10.91亿股股份，占于本公告日期该公司全部已发行股本约45.37%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"source_url":"http://www.zhitongcaijing.com/content/detail/699072.html","is_publish_highlight":false},{"id":"2226509053","title":"港股异动 | 心通医疗-B(2160.HK)高开4.17% 获控股股东斥3436万元增持股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2226509053","media":"金融界网站","top":-1,"share":"https://www.laohu8.com/m/news/2226509053?lang=zh_CN&edition=full","pubTime":"2022-04-11 09:26","pubTimestamp":1649640395,"startTime":"0","endTime":"0","summary":"格隆汇4月11日丨心通医疗-B(2160.HK)高开4.17%，报3港元，总市值72亿港元。该公司昨日发布公告，公司董事会已获公司控股股东微创医疗科学有限公司告知，自2022年4月6日至4月8日，Shanghai MicroPort Limited（微创医疗科学有限公司的全资子公司，及公司控股股东）按平均价每股约2.8723港元，于公开市场购入合共1196.4万股公司股份，涉资3436.42万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"source_url":"http://hk.jrj.com.cn/2022/04/11092636299672.shtml","is_publish_highlight":false},{"id":"2226509563","title":"港股开盘(4.11)︱恒指跌0.84% 腾讯控股(00700)与阿里巴巴-SW(09988)均低开近1%","url":"https://stock-news.laohu8.com/highlight/detail?id=2226509563","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2226509563?lang=zh_CN&edition=full","pubTime":"2022-04-11 09:24","pubTimestamp":1649640240,"startTime":"0","endTime":"0","summary":"红筹指数跌0.69%，报4083.99点。蓝筹方面，腾讯控股早盘低开0.97%，报366.00港元，拖累指数15.23点。公司预计2022年第一季度实现归属于公司股东的净利润约为人民币16.43亿元，较2021年第一季度的人民币15.00亿元，同比增长约9.54%;2022年第一季度的基本每股收益预计约为人民币0.56元，较2021年第一季度的人民币0.52元，同比增长约7.69%。KN026-203用于治疗乳腺癌及胃癌的初步积极结果已于2021年圣安东尼奥乳腺癌研讨会上发表。该股早盘高开4.17%，报3.00港元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"source_url":"http://www.zhitongcaijing.com/content/detail/699068.html","is_publish_highlight":false},{"id":"2225593571","title":"港股异动 | 心通医疗-B(2160.HK)跌8.39% 瑞信降低其目标价","url":"https://stock-news.laohu8.com/highlight/detail?id=2225593571","media":"格隆汇","top":-1,"share":"https://www.laohu8.com/m/news/2225593571?lang=zh_CN&edition=full","pubTime":"2022-04-07 11:16","pubTimestamp":1649301360,"startTime":"0","endTime":"0","summary":"格隆汇4月7日丨心通医疗-B(2160.HK)跌8.39%，报2.73港元，总市值65亿港元。瑞信报告指出，心通医疗-B(2160.HK)去年下半年收入按年增长76.1%，达到1.15亿人民币，而去年...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"source_url":"http://finance.eastmoney.com/a/202204072334814990.html","is_publish_highlight":false},{"id":"2225159840","title":"港股异动 | 心通医疗-B(02160)盘中跌超7% 瑞信将其达成收支平衡的时间表推迟到2025年左右","url":"https://stock-news.laohu8.com/highlight/detail?id=2225159840","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2225159840?lang=zh_CN&edition=full","pubTime":"2022-04-07 10:40","pubTimestamp":1649299217,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，心通医疗-B(02160)盘中跌超7%，截至发稿，跌6.71%，报2.78港元，成交额1491.53万港元。瑞信发表研究报告称，心通医疗去年下半年收入同比增长76.1%，达到1.15亿元，而去年下半年的净亏损缩减到1.13亿元。收入和亏损均超出该行预期。该行将其达成收支平衡的时间表推迟到2025年左右，预计2022/23年亏损分别扩大至1.7亿/2.57亿元人民币，目标价由6.45港元下调至4.2港元。维持“跑赢大市”评级。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"source_url":"http://www.zhitongcaijing.com/content/detail/697285.html","is_publish_highlight":false},{"id":"2225598884","title":"【港股通】心通医疗(02160)跌超3% 遭瑞信下调目标价34.9%至4.2港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2225598884","media":"凤凰网港股","top":-1,"share":"https://www.laohu8.com/m/news/2225598884?lang=zh_CN&edition=full","pubTime":"2022-04-07 09:52","pubTimestamp":1649296358,"startTime":"0","endTime":"0","summary":"心通医疗遭瑞信下调目标价，早盘股价震荡下行，最新报2.89港元，跌3.02%，成交额203.38万港元。瑞信发研报指，心通医疗2021年下半年收入同比增长76.1%至1.15亿元，而净亏损收窄至1.13亿元。其收入与净亏损表现均高出该行预期，毛利率增长高于预期。该行根据管理层指引，上调近期运营支出并参考21财年的实际情况，将2022/23的净亏损扩大1082%/330%。该行将公司的利润盈亏平衡点推迟到2025财年左右。目标价从6.45港元下调34.9%至4.2港元并维持“跑赢大市”评级。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"source_url":"http://hknews.szfuit.com/newRssInfo/feed?original_id=566e163e221fd514c72ff82a0e4606bf","is_publish_highlight":false},{"id":"2225323445","title":"【券商聚焦】瑞信下调心通医疗-B(02160)目标价34.9%至4.2港元 料其净亏损仍将持续","url":"https://stock-news.laohu8.com/highlight/detail?id=2225323445","media":"凤凰网港股","top":-1,"share":"https://www.laohu8.com/m/news/2225323445?lang=zh_CN&edition=full","pubTime":"2022-04-06 11:40","pubTimestamp":1649216411,"startTime":"0","endTime":"0","summary":"瑞信发研报指，心通医疗-B2021年下半年收入同比增长76.1%至1.15亿元，而净亏损收窄至1.13亿元。其收入与净亏损表现均高出该行预期，毛利率增长高于预期。同时，预计公司在22财年对其几款TMV产品进入FIM试验阶段。该行根据管理层指引，上调近期运营支出并参考21财年的实际情况，将2022/23的净亏损扩大1082%/330%。该行将公司的利润盈亏平衡点推迟到2025财年左右。目标价从6.45港元下调34.9%至4.2港元并维持“跑赢大市”评级。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"source_url":"http://hknews.szfuit.com/newRssInfo/feed?original_id=1e31ddfb862697f4307b53e4c78c04c9","is_publish_highlight":false},{"id":"2225534860","title":"瑞信：维持心通医疗-B(02160)“跑赢大市”评级 目标价降34.9%至4.2港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2225534860","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2225534860?lang=zh_CN&edition=full","pubTime":"2022-04-06 10:27","pubTimestamp":1649212066,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，瑞信发布研究报告称，维持心通医疗-B(02160)“跑赢大市”评级，上调2022/23年净亏损预测至1.7/2.57亿元人民币，目标价由6.45港元降至4.2港元。报告中称，公司2021年下半年收入增长及亏损收窄，均胜于预期。管理层给予指引，2022年心脏相关经导管主动脉瓣置换(TAVR)产品渗透量增长至4000单位。另经导管二尖瓣(TMV)产品计划实行数个人体首次试用于临床试验。公司以微创手术的全球销售网络对外扩张。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"source_url":"http://www.zhitongcaijing.com/content/detail/696374.html","is_publish_highlight":false},{"id":"2225539168","title":"*瑞信降心通医疗-B(02160)目标价34.9%至4.20港元 维持“跑赢大市”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2225539168","media":"凤凰网港股","top":-1,"share":"https://www.laohu8.com/m/news/2225539168?lang=zh_CN&edition=full","pubTime":"2022-04-06 08:56","pubTimestamp":1649206578,"startTime":"0","endTime":"0","summary":"瑞信将心通医疗-B(02160)目标价从6.45港元下调34.9%至4.20港元，维持“跑赢大市”评级。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"source_url":"http://hknews.szfuit.com/newRssInfo/feed?original_id=7f8933dfa64eef5d8e9e745053530d73","is_publish_highlight":false}],"profile":{"stockEarnings":[{"period":"1week","weight":0.2206},{"period":"1month","weight":0.5662},{"period":"3month","weight":0.3295},{"period":"6month","weight":-0.1044},{"period":"1year","weight":-0.7898},{"period":"ytd","weight":-0.1137}],"websiteUrl":null,"compareEarnings":[{"period":"1week","weight":0.0306},{"period":"1month","weight":0.0767},{"period":"3month","weight":0.0147},{"period":"6month","weight":-0.0648},{"period":"1year","weight":-0.248},{"period":"ytd","weight":-0.0717}],"name":"心通医疗-B","description":"微创心通医疗科技有限公司是一家主要从事医疗器械行业的中国投资控股公司。该公司主要从事心脏瓣膜疾病领域经导管及手术解决方案的研发和商业化。该公司主要产品包括第一代经导管主动脉瓣植入（TAVI）产 品“VitaFlow”和第二代TAVI产品“VitaFlow II”。该公司主要于国内市场开展业务。","exchange":"SEHK","nameEN":"CARDIOFLOW-B","compareStock":{"symbol":"HSI","name":"恒生指数"}},"isWeiXinMini":false,"pagemeta":{"title":"心通医疗-B(02160)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供心通医疗-B(02160)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"心通医疗-B,02160,心通医疗-B股票,心通医疗-B股票老虎,心通医疗-B股票老虎国际,心通医疗-B行情,心通医疗-B股票行情,心通医疗-B股价,心通医疗-B股市,心通医疗-B股票价格,心通医疗-B股票交易,心通医疗-B股票购买,心通医疗-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情"}}